management of muscle invasive urothelial carcinoma of the bladder, but it confers only a modest survival advantage. Patients with pathologic progression on NC have poor outcomes and may benefit from upfront cystectomy. We previously demonstrated that phenotypic epithelialmesenchymal transition (EMT) is associated with advanced stage and grade. This study pursued the predictive value of EMT signature effectors of bladder cancer therapeutic response to NC.
METHODS: A tissue microarray (TMA) was constructed with matched pre-NC transurethral resection (TUR) specimens and post-NC cystectomy specimens from the same patients (N¼69) with specimens from patients managed with surgery alone serving as control (N¼21). TMA sections were immunostained for the EMT biomarkers E-cadherin (epithelial marker), N-cadherin and Vimentin (mesenchymal markers) and b-catenin (EMT effector) and staining intensity was scored by two blinded reviewers. Data was statistically analyzed using 1-way ANOVA and T-tests.
RESULTS: Increased expression of the mesenchymal markers Vimentin and N-cadherin on TUR specimen was associated with nodal metastasis and extravesical disease (ypT3 or Nþ) at the time of cystectomy (P¼0.019 and 0.002, respectively). Decreased Vimentin and N-cadherin expression independently predicted complete pathologic response to NC (ypT0, P<0.001 and 0.024, respectively). In post-NC cystectomy specimens, only N-cadherin expression was correlated with pathologic stage (P¼0.004). In TUR specimens from patients managed with surgery alone, increased expression of bcatenin and N-cadherin predicted extravesical disease at the time of cystectomy (P¼0.033 and 0.007, respectively). When comparing preand post-NC specimens, treatment with platinum-based NC induced a mixed EMT picture, with stable b-catenin and N-cadherin expression and decreased E-cadherin and Vimentin expression, relative to control patients. Expression patterns in metastatic lymph node tissue was inconsistent.
CONCLUSIONS: Expression of EMT markers have potential value in predicting pathologic response to cisplatin-based NC. Further validation is necessary to correlate these findings with clinical outcomes and establish these as novel biomarkers of adverse response to NC towards the goal of optimizing patient selection for NC.
Source of Funding: IRG 85-001-25

MP65-17
MICRORNA-411 DOWNREGULATION PROMOTES TUMORIGENESIS AND INHIBITS CHEMOTHERAPY SENSITIVITY BY UPREGULATING MLLT11 EXPRESSION IN HUMAN BLADDER CANCER.
Xiaohui Hua*, tuxedo park, NY; Honglei Jin, Haishan Huang, Wenzhou, China, People's Republic of; JingXia Li, Chuanshu Huang, tuxedo park, NY INTRODUCTION AND OBJECTIVES: Although miR-411 was positively correlated with survival (>3 years) in bladder cancer patients according to the TCGA database, the functions and potential mechanisms of miR-411 has rarely been explored in human bladder cancer. The present study explores the relationship between miR-411 and tumorigenesis as well as chemotherapy sensitivity in human bladder cancer.
METHODS: miRNA high-throughout deep sequencing was performed to analyze expression levels of miRNAs in 10 mouse bladder cancer tissues from BBN-treated mice in comparison to vehicle-treated mouse bladder tissues. The downregulation of miR-411 was confirmed by quantitative real-time PCR. Human bladder cancer cells T24 and UMUC3 were used to determine the effects of miR-411 on cell growth in vivo and xenograft tumorigenic nude mice models to examine the effect of miR-411 on tumorigenicity in vivo.
RESULTS: We screened 1900 known miRNAs and first discovered that miR-411 was one of major miRNAs that was downregulated in a n-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN)-induced BC mouse model. This miR-411 downregulation was also observed in human BC tissues and cell lines. Overexpression of miR-411 suppressed anchorage-independent growth and proliferation in T24 and UMUC3 cells and induced cell cycle arrest in G2/M phase. Mechanistic studies revealed that overexpression of miR-411 repressed expression of ALL1-fused gene from the chromosome 1q (MLLT11) by binding to the 3'-untranslated region of MLLT11 mRNA, induced p21 expression, and caused cell cycle arrest at the G2/M phase, in turn inhibiting BC tumorigenic growth. Ectopic expression of MLLT11 or knockdown of p21 reversed the inhibitory effect of miR-411 on BC cells. The clinical significance of miR-411 was investigated that miR-411 increases chemotherapeutic drugs epirubicin (EPI) and mitomycin-C (MMC) sensitivity in BC cells.
CONCLUSIONS: miR-411 is downregulated in both human and mouse BCs, miR-411 overexpression suppressed BC cell monolayer and anchorage-independent growth and induced G2/M cell cycle arrest. Due to the inhibitory effect of miR-411 in BC, miR-411 may serve as a therapeutic strategy for the treatment of BC patients.
Source of Funding: NIH/NCI CA177665 and CA165980, and NIH/NIEHS ES000260
MP65-18 BLADDER CANCER EXTRACELLULAR VESICLES FACILITATE METASTASIS
Yu-Ru Liu*, Yi-Fen Lee, Peng-Nien Yin, Edward Messing, ROCHESTER, NY
INTRODUCTION AND OBJECTIVES:
Tumor-derived extracellular vesicles (EV) have been shown to function as sentinels to optimize the tumor microenvironment in favour of metastasis. However, the impact of bladder cancer derived EV (BCEV) on the pre-metastatic niche (PMN) formation remains largely unknown. To study how the primary BC drives metastasis, a feasible experimental model was established, and the metastasis-promoting BCEV were characterized. Our ultimate goal is to identify EV-based liquid biopsy markers of BC progression.
METHODS: To select a subpopulation of adaptable BC cells that drive cancer metastasis, murine MB49 cells were re-implanted into C57BL/6 mice. Single clone selection of metastasis-prone sublines was performed, and the metastasis ability was confirmed in vivo. Mice were intravenously primed with EV and subsequently MB49-luc reporter cells were injected to determine EV roles in PMN formation. The tumor growth was monitored with the IVIS live imaging system. Proteomic analysis of EV cargos was performed by TMT mass spectrometry and validated by Western blot. Proteins of interests were characterized via the shRNA approach. Candidate protein expression in a human BC dataset was analysed and correlated with their clinical outcomes.
RESULTS: By single clone selection, we obtained a subline of MB49 cells (metastasis MB49. met-MB49) which have distinct stem-like morphology in vitro. In vivo characterization showed that this subline are pro-metastasis where mice developed lung and liver metastases within three weeks of tumor implantation, whereas none were found in MB49 parental cell-implanted mice. The met-MB49 cells secrete EVs at a higher rate, and more importantly, met-MB49 EV-primed mice developed severe lung and liver metastases much earlier than the MB49 parental EV-primed mice. Analysing the EV protein cargo, we identified two extracellular matrix (ECM) component proteins, fibulin-2 and decorin, which were highly enriched in the mp-MB49 EVs and whose expression was inversely correlated with patient survival. This implies that the EV function to remodel the ECM in favor of metastasis.
CONCLUSIONS: Our study established a murine MB49 syngeneic model for studying BC metastasis. With this model, we discovered high expression levels of two cancer-related ECM components in the EV derived from a rapidly metastasizing cell line, and identified candidates for EV-based biomarkers for predicting BC metastasis. It also sheds light on EV's role in ECM remodelling and provides a new strategy in preventing metastasis. Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e865
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